Thomas Mair
Thomas Mair
M. Sc.
  • Working area 1
Languages
German (Mother tongue)
English

Publications

2023

Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
Dyshlovoy S, Hauschild J, Venz S, Krisp C, Kolbe K, Zapf S, Heinemann S, Fita K, Shubina L, Makarieva T, Guzii A, Rohlfing T, Kaune M, Busenbender T, Mair T, Moritz M, Poverennaya E, Schlüter H, Serdyuk V, Stonik V, Dierlamm J, Bokemeyer C, Mohme M, Westphal M, Lamszus K, von Amsberg G, Maire C
MOL PHARMACEUT. 2023;20(10):4994-5005.

PKA mediates modality-specific modulation of the mechanically gated ion channel PIEZO2
Schaefer I, Verkest C, Vespermann L, Mair T, Voß H, Zeitzschel N, Lechner S
J BIOL CHEM. 2023;299(6):104782.

Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level
Voß H, Godbole S, Schlumbohm S, Schumann Y, Peng B, Mynarek M, Rutkowski S, Dottermusch M, Dorostkar M, Koshunov A, Mair T, Pfister S, Neumann P, Hartmann C, Weis J, Liesche-Starnecker F, Guan Y, Schlüter H, Schüller U, Krisp C, Neumann J
bioRxiv. 2023;2023:.

Letzte Aktualisierung aus dem FIS: 14.05.2024 - 04:30 Uhr